Stock Market Reviews

DOCS (Doximity, Inc.) News

Get the latest news, insights, and market updates on DOCS (Doximity, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• 3 Growth Stocks with Explosive Upside
  Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
  Dec 18, 2025 - $DOCS
• How Analyst Upgrades Highlighting AI Tools And Ad Shift Potential At Doximity (DOCS) Has Changed Its Investment Story
  Earlier this month, Morgan Stanley and Raymond James upgraded Doximity after highlighting its strong free cash flow, balance sheet strength, and expanded AI-enabled workflow tools that are increasingly embedded in clinicians’ daily routines. Analysts also pointed to potential benefits from tighter rules on direct-to-consumer drug advertising, which could steer more pharmaceutical marketing budgets toward Doximity’s physician-focused platform. Now we’ll examine how this renewed focus on...
  Dec 18, 2025 - $DOCS
• 3 New Year’s Resolution Stocks That Could Turn Around in 2026
  Three companies with less-than-stellar performance records in 2025 may have the fundamentals needed to reverse course in the new year.
  Dec 18, 2025 - $DOCS
• 1 Stock Under $50 for Long-Term Investors and 2 Facing Headwinds
  The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
  Dec 17, 2025 - $DOCS
• Tempus AI Turns Non-GAAP Profit on Surging Genomics and Data
  Tempus AI posts first positive adjusted EBITDA as genomics testing accelerates and data bookings broaden. Zacks Rank #3 (Hold) with mixed Style Scores.
  Dec 17, 2025 - $DOCS
• Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up
  Tempus AI's Q3 revenue surged as oncology and hereditary testing led the way, margins improved, and pricing tailwinds and regulatory milestones took shape.
  Dec 16, 2025 - $DOCS
• Doximity (DOCS): Taking Stock of Valuation After Analyst Upgrades on AI Tools and Growth Outlook
  Several Wall Street firms have just turned more positive on Doximity (DOCS), pointing to its expanding AI workflow tools, tighter integration into clinicians daily routines, and an appealing valuation after a sharp stock pullback. See our latest analysis for Doximity. After a steep 90 day share price return of minus 38.05 percent from earlier policy jitters, Doximity now trades around 44.65 dollars, with one year total shareholder return of minus 16.2 percent but a still impressive three year...
  Dec 16, 2025 - $DOCS
• Costco downgraded, Dollar General upgraded: Wall Street’s top analyst calls
  The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential Top 5 Upgrades: JPMorgan upgrad
  Dec 16, 2025 - $DOCS
• Tempus AI Near $75 Target? Valuation, Upside and Risks
  Tempus AI's rally meets a $75 target. Here's how valuation, catalysts, risks, and key numbers set up the risk-reward into 2026.
  Dec 15, 2025 - $DOCS
• Doximity (DOCS) Ascends While Market Falls: Some Facts to Note
  Doximity (DOCS) closed the most recent trading day at $44.65, moving +1.82% from the previous trading session.
  Dec 15, 2025 - $DOCS